Targeting of angiogenic endothelial cells at sites of inflammation by dexamethasone phosphate–containing RGD peptide liposomes inhibits experimental arthritis
Open Access
- 30 March 2006
- journal article
- research article
- Published by Wiley in Arthritis & Rheumatism
- Vol. 54 (4) , 1198-1208
- https://doi.org/10.1002/art.21719
Abstract
Objective: To investigate whether RGD peptide–exposing long circulating polyethylene glycol (PEG) liposomes (RGD‐PEG–L) targeted to αvβ3 integrins expressed on angiogenic vascular endothelial cells (VECs) are able to bind VECs at sites of inflammation and whether such liposomes containing dexamethasone phosphate (DEXP) can be used as carriers to interfere with the development of experimental arthritis.Methods: Binding and internalization of RGD‐PEG–L were studied by fluorescence‐activated cell sorting and confocal microscopy using fluorescently labeled liposomes. Radiolabeled liposomes were used to test in vivo pharmacokinetics and inflammation site targeting in lipopolysaccharide (LPS)–induced inflammation and adjuvant‐induced arthritis (AIA) in rats. In vivo inflammation targeting was visualized by intravital microscopy using fluorescently labeled RGD‐PEG–L. Therapeutic efficacy of DEXP‐encapsulating RGD‐PEG–L compared with nontargeted liposomes was evaluated in rats with AIA.Results: RGD‐PEG–L bound to and were taken up by proliferating human VECs in vitro. In vivo, increased targeting of radiolabeled RGD‐PEG–L to areas of LPS‐induced inflammation in rats was observed. Specific association with the blood vessel wall at the site of inflammation was confirmed by intravital microscopy. One single intravenous injection of DEXP encapsulated in RGD‐PEG–L resulted in a strong and long‐lasting antiarthritic effect in rat AIA.Conclusion: RGD‐targeted PEG liposomes represent an endothelial cell–specific drug delivery system that targets VECs at sites of inflammation. Use of these liposomes to deliver DEXP to VECs at arthritis‐affected sites proved efficacious in rat adjuvant arthritis. These data indicate that VECs have an essential role in the inflammation process and suggest the possibility of using VEC targeting for therapeutic intervention in inflammatory processes such as arthritis.Keywords
This publication has 48 references indexed in Scilit:
- Antiangiogenic effects of anti–tumor necrosis factor α therapy with infliximab in psoriatic arthritisArthritis & Rheumatism, 2004
- A Novel Family ofl-Amino Acid-Based Biodegradable Polymer−Lipid Conjugates for the Development of Long-Circulating Liposomes with Effective Drug-Targeting CapacityBioconjugate Chemistry, 2003
- LIGAND-TARGETED LIPOSOMES DIRECTED AGAINST PATHOLOGICAL VASCULATUREJournal of Liposome Research, 2002
- N-Methylated Cyclic RGD Peptides as Highly Active and Selective αVβ3Integrin AntagonistsJournal of Medicinal Chemistry, 1999
- Matrix Metalloproteinase-19 in Capillary Endothelial Cells: Expression in Acutely, but Not in Chronically, Inflamed SynoviumExperimental Cell Research, 1999
- Adhesion molecules: a new target for immunoliposome‐mediated drug deliveryFEBS Letters, 1995
- Immunospecific targeting of liposomes to cells: a novel and efficient method for covalent attachment of Fab' fragments via disulfide bondsBiochemistry, 1981
- Culture of Human Endothelial Cells Derived from Umbilical Veins. IDENTIFICATION BY MORPHOLOGIC AND IMMUNOLOGIC CRITERIAJournal of Clinical Investigation, 1973
- A rapid and sensitive sub-micro phosphorus determinationAnalytica Chimica Acta, 1961
- A RAPID METHOD OF TOTAL LIPID EXTRACTION AND PURIFICATIONCanadian Journal of Biochemistry and Physiology, 1959